Immunobiology of allogeneic peripheral blood mononuclear cells mobilized with granulocyte-colony stimulating factor.

Abstract:

:The use of mobilized peripheral blood (PB) stem cells for autologous transplantation initially generated much enthusiasm because of enhanced engraftment in comparison to marrow stem cells and avoidance of general anesthesia for the donor. Its application to the allogeneic setting seemed inevitable. For obvious ethical reasons, allogeneic donors are mobilized with cytokines only, mainly granulocyte colony-stimulating factor (G-CSF). Results from preliminary studies suggest that in comparison to standard bone marrow transplants, outcomes such as engraftment, host-versus-graft reaction, graft-versus-host disease, graft-versus-leukemia and immunological reconstitution may be different. Surprisingly, G-CSF, previously recognized as a late acting lineage-specific factor for neutrophil production, not only disrupts homeostasis between stem cells and their microenvironment, but also induces significant quantitative and qualitative changes in the accessory cell compartment, affecting lymphocytes, monocytes, natural killer, dendritic, and stromal cells. Furthermore, mobilization of huge numbers of non-professional antigen presenting cells (CD34+ stem cells) amplifies the tolerizing potential of PB stem cell grafts. Thus, G-CSF mobilization provides PB transplants with different immunobiologic properties in comparison to standard bone marrow grafts. Whether these immunobiologic differences will lead to better transplant outcomes remains to be shown through much awaited results of large randomized clinical trials.

journal_name

Bone Marrow Transplant

authors

Gyger M,Stuart RK,Perreault C

doi

10.1038/sj.bmt.1702464

subject

Has Abstract

pub_date

2000-07-01 00:00:00

pages

1-16

issue

1

eissn

0268-3369

issn

1476-5365

journal_volume

26

pub_type

杂志文章,评审
  • Veno-occlusive disease after high-dose busulfan-melphalan in neuroblastoma.

    abstract::Survival for high-risk neuroblastoma patients is still suboptimal. Although stem cell transplantation (SCT) is used, there is no consensus as to which conditioning regimen has the greatest efficacy and fewest toxicities. We assessed the incidence of and risk for hepatic veno-occlusive disease (VOD) for neuroblastoma p...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/s41409-018-0298-y

    authors: Schechter T,Perez-Albuerne E,Lin TF,Irwin MS,Essa M,Desai AV,Frangoul H,Yanik G,Dupuis LL,Jacobsohn D,Kletzel M,Ranalli M,Soni S,Seif AE,Grupp S,Dvorak CC

    更新日期:2020-03-01 00:00:00

  • Administration of recombinant human granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation in children with acute myelogenous leukemia: a note of caution.

    abstract::A series of 22 consecutive pediatric patients undergoing ABMT for treatment of primary AML was reviewed in an efficacy analysis of recombinant human granulocytemacrophage colony-stimulating factor (rhGM-CSF). Treatment with at least two cycles of chemotherapy and a standard conditioning regimen of busulfan and cycloph...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:

    authors: Calderwood S,Doyle JJ,Hitzler JK,Saunders EF,Freedman MH

    更新日期:1996-07-01 00:00:00

  • Comparison of allogeneic T cell-depleted peripheral blood stem cell and bone marrow transplantation: effect of stem cell source on short- and long-term outcome.

    abstract::We report the results of a retrospective single-center study comparing engraftment, acute and chronic GVHD, relapse and survival in patients with malignant hematological disorders transplanted with allogeneic peripheral blood stem cells (alloPBSCT, n = 40) or bone marrow cells (alloBMT, n = 42). All transplants were T...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1703024

    authors: Barge RM,Brouwer RE,Beersma MF,Starrenburg CW,Zwinderman AH,Hale G,Waldmann H,den Ottolander GJ,Falkenburg JH,Willemze R,Fibbe WE

    更新日期:2001-05-01 00:00:00

  • Paecilomyces varioti fungemia in a bone marrow transplant patient.

    abstract::Paecilomyces varioti, a fungus resembling penicillium spp, has been described in conjunction with impaired host defence or foreign body implants. We report a case of Paecilomyces varioti catheter-related fungemia that occurred during neutropenia in an allogeneic BMT patient receiving antifungal prophylaxis with flucon...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Shing MM,Ip M,Li CK,Chik KW,Yuen PM

    更新日期:1996-02-01 00:00:00

  • European results of matched unrelated donor bone marrow transplantation for chronic myeloid leukemia. Impact of HLA class II matching. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

    abstract::We have retrospectively analyzed the impact of prognostic factors on the outcome of serologically HLA-matched unrelated donor (UD) BMT for CML. For this purpose, we have studied a cohort of 366 patients transplanted in Europe between January 1985 and December 1994. The median age of the 211 males and 155 females was 3...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1700844

    authors: Devergie A,Apperley JF,Labopin M,Madrigal A,Jacobsen N,Carreras E,Prentice HG,Jouet JP,Kolb HJ,Herstenstein B,Bacigalupo A,Evensen SA,Ljungman P,de Witte T,Reiffers J,Nagler A,Clark RE,Goldman JM,Gratwohl A

    更新日期:1997-07-01 00:00:00

  • Stem cell transplant for Waldenström macroglobulinemia: an underutilized technique.

    abstract::Waldenström macroglobulinemia is a highly chemosensitive lymphoplasmacytic lymphoma with response rates of 90% to first-line chemotherapy. The fraction of patients undergoing stem cell transplant for this disorder appears to be lower than that of patients with multiple myeloma. The indolent nature and favorable geneti...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:10.1038/bmt.2011.175

    authors: Gertz MA,Reeder CB,Kyle RA,Ansell SM

    更新日期:2012-09-01 00:00:00

  • Allogeneic transplant can abrogate the risk of relapse in the patients of first remission acute myeloid leukemia with detectable measurable residual disease by next-generation sequencing.

    abstract::In patients with acute myeloid leukemia (AML) consolidation treatment options are between allogeneic hematopoietic stem cell transplantation (HCT) and chemotherapy, based on disease risk at the time of initial presentation and age. Measurable residual disease (MRD) following induction chemotherapy could be incorporate...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/s41409-020-01165-x

    authors: Ahn JS,Kim T,Jung SH,Ahn SY,Jung SY,Song GY,Kim M,Yang DH,Lee JJ,Choi S,Lee JY,Park SK,Moon JH,Lee HY,Kim KH,Cai Y,Yi SY,Novitzky-Basso I,Zhang Z,Kim HJ,Kim DDH

    更新日期:2020-12-05 00:00:00

  • Immune hemolysis involving non-ABO/RhD alloantibodies following hematopoietic stem cell transplantation.

    abstract::We report two cases of severe alloimmune hemolysis after hematopoietic stem cell (HSC) transplant resulting from an anti-Jk(a). The time course of hemolysis and Jk phenotypes of the donor and recipient in the cases reported suggest that the antibody was produced by donor-derived passenger lymphocytes. Retrospective an...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1703074

    authors: Young PP,Goodnough LT,Westervelt P,Diersio JF

    更新日期:2001-06-01 00:00:00

  • Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipients.

    abstract::The efficacy and safety of oral valganciclovir was compared to ganciclovir i.v. in pre-emptive treatment of cytomegalovirus (CMV) in T-cell-depleted allogeneic stem cell transplant (allo-SCT) recipients. A therapeutic guideline was developed to allow the safe application of valganciclovir in allo-SCT recipients requir...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1705311

    authors: van der Heiden PL,Kalpoe JS,Barge RM,Willemze R,Kroes AC,Schippers EF

    更新日期:2006-04-01 00:00:00

  • Bacteremias in children receiving hemopoietic SCT.

    abstract::The incidence of bacteremia following hemopoietic SCT (HSCT) changes over time from the procedure. The first 30 days have the highest incidence, both in autologous and allogeneic HSCT recipients. In the following periods, bacteremia is a frequent complication in allogeneic HSCT, especially from alternative donors. Gra...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2008.66

    authors: Castagnola E,Faraci M,Moroni C,Bandettini R,Caruso S,Bagnasco F,Caviglia I,Natalizia AR,de Fazio V,Morreale G,Lanino E,Dini G,Haupt R

    更新日期:2008-06-01 00:00:00

  • High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas.

    abstract::Peripheral T cell lymphomas (PTCL) have a poorer prognosis after conventional treatment than do high-grade B cell lymphomas. The place for high-dose therapy (HDT) with autologous stem cell support in these patients is still not clear. Forty patients, 10 women and 30 men, median age 41.5 years (range 16-61) with PTCL w...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,多中心研究

    doi:10.1038/sj.bmt.1702867

    authors: Blystad AK,Enblad G,Kvaløy S,Berglund A,Delabie J,Holte H,Carlson K,Kvalheim G,Bengtsson M,Hagberg H

    更新日期:2001-04-01 00:00:00

  • Role of HLA in hematopoietic SCT.

    abstract::HLA disparity between hematopoietic stem cell (HSC) donor and recipient triggers T-cell and NK-cell allorecognition, and induces the GVHD, GVL effect and/or may cause an engraftment failure. This review will cover the scope of human genomic variation, the methods of HLA typing and interpretation of high-resolution HLA...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:10.1038/bmt.2008.288

    authors: Nowak J

    更新日期:2008-10-01 00:00:00

  • Treatment of gonadal damage in recipients of allogeneic or autologous transplantation for haematological malignancies.

    abstract::Management of iatrogenic gonadal reproductive failure and sexual morbidity assumes a priority, especially in young recipients of high-dose chemotherapy and stem cell transplantation (SCT). Hormone replacement treatment (HRT) is beneficial for correction of sexual symptoms and osteoporosis in both sexes, especially in ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:10.1038/sj.bmt.1703721

    authors: Chatterjee R,Kottaridis PD

    更新日期:2002-11-01 00:00:00

  • Plasmodium vivax malaria after autologous bone marrow transplantation: an unusual complication.

    abstract::We report the case of unusually early infection by Plasmodium vivax after autologous bone marrow transplantation in a 20-year-old female from Bangladesh affected by acute myelogenous leukemia in first complete remission (CR) who underwent autologous bone marrow transplantation in our center. During the aplastic phase ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Salutari P,Sica S,Chiusolo P,Micciulli G,Plaisant P,Nacci A,Antinori A,Leone G

    更新日期:1996-10-01 00:00:00

  • Early allogeneic blood stem cell transplantation after modified conditioning therapy during marrow aplasia: stable remission in high-risk acute myeloid leukemia.

    abstract::Two patients with high-risk acute myeloid leukemia (AML) whose bone marrow aspirates showed more than 25% blasts between 2 and 4 weeks after the first induction chemotherapy immediately received modified conditioning therapy with intravenous busulfan at 50% of the usual dose and fludarabine, before hematologic recover...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1702819

    authors: Platzbecker U,Thiede C,Freiberg-Richter J,Röllig C,Helwig A,Schäkel U,Mohr B,Schaich M,Ehninger G,Bornhäuser M

    更新日期:2001-03-01 00:00:00

  • Monitoring of cytomegalovirus reactivation after allogeneic stem cell transplantation: comparison of an antigenemia assay and quantitative real-time polymerase chain reaction.

    abstract::Cytomegalovirus (CMV) antigenemia and quantitative real-time polymerase chain reaction (PCR) were compared for monitoring of CMV reactivation after allogeneic stem cell transplantation. The number of CMV antigen-positive cells by the antigenemia assay and the level of CMV DNA by real-time PCR correlated well. The sens...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1703513

    authors: Yakushiji K,Gondo H,Kamezaki K,Shigematsu K,Hayashi S,Kuroiwa M,Taniguchi S,Ohno Y,Takase K,Numata A,Aoki K,Kato K,Nagafuji K,Shimoda K,Okamura T,Kinukawa N,Kasuga N,Sata M,Harada M

    更新日期:2002-04-01 00:00:00

  • Hematopoietic recovery from host progenitors with normal karyotype devoid of Philadelphia chromosome in a patient with CML after allogeneic BMT.

    abstract::A male patient with CML received a BMT from his sister and developed chronic GVHD. The host-origin normal karyotype (46,XY) was identified for the first time in the 60th month after BMT. Detection of Y-chromosome-specific DNA in BM and peripheral blood (PB) showed that all BM samples obtained 6 months from BMT were po...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Okamoto T,Kanamaru A,Wada H,Takemoto Y,Kakishita E,Hashimoto T,Furuyama J,Nagai K

    更新日期:1993-07-01 00:00:00

  • Donor leukocyte infusions in relapsed Hodgkin's lymphoma following allogeneic stem cell transplantation: CD3+ cell dose, GVHD and disease response.

    abstract::Nine patients with advanced Hodgkin's lymphoma (HL) who had undergone allogeneic stem cell transplantation (allo-SCT) received donor leukocyte infusions (DLIs) for treatment of persistent or progressive disease (PD). A total of 15 DLIs were performed, with four patients receiving more than one DLI. In four patients, p...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1704621

    authors: Anderlini P,Acholonu SA,Okoroji GJ,Andersson BS,Couriel DR,De Lima MJ,Donato ML,Khouri IF,Giralt SA,Ueno NT,Champlin RE

    更新日期:2004-09-01 00:00:00

  • High-dose cyclophosphamide-induced myocardial damage during BMT: assessment by positron emission tomography.

    abstract::Despite its potential to cause myocardial damage, high-dose CY in doses up to 200 mg/kg is an integral part of preparative regimens for BMT. Conventional tests, such as an electrocardiogram or echocardiogram, have lacked sensitivity in prediction of cardiotoxicity in this patient population. We prospectively compared ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Gardner SF,Lazarus HM,Bednarczyk EM,Creger RJ,Miraldi FD,Leisure G,Green JA

    更新日期:1993-08-01 00:00:00

  • Influence of total nucleated cell dose from marrow harvests on outcome in patients with acute myelogenous leukemia undergoing autologous transplantation.

    abstract::This retrospective study was conducted to determine whether the total number of nucleated cells (TNC)/kg collected at marrow harvest was associated with outcome in 151 patients with acute myelogenous leukemia (AML) who received an autologous purged (n = 67) or non-purged (n = 84) marrow transplant. At the time of tran...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Demirer T,Gooley T,Buckner CD,Petersen FB,Lilleby K,Rowley S,Sanders J,Storb R,Appelbaum FR,Bensinger WI

    更新日期:1995-06-01 00:00:00

  • Do patients with metastatic and recurrent rhabdomyosarcoma benefit from high-dose therapy with hematopoietic rescue? Report of the German/Austrian Pediatric Bone Marrow Transplantation Group.

    abstract::Patients with primary metastatic or recurrent rhabdomyosarcoma (RMS) have a very poor prognosis. Since high-dose chemotherapy (HDC) +/- TBI was thought to improve survival, many centers performed this therapy using different types of hematopoietic rescue (auto BM or PBSC, allo BM). This is a retrospective, multi-cente...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,多中心研究

    doi:10.1038/sj.bmt.1700628

    authors: Koscielniak E,Klingebiel TH,Peters C,Hermann J,Burdach ST,Bender-Götze C,Müller-Weihrich ST,Treuner J

    更新日期:1997-02-01 00:00:00

  • Open-label, single arm, multicenter phase II study of VIDL induction chemotherapy followed by upfront autologous stem cell transplantation in patients with advanced stage extranodal NK/T-cell lymphoma.

    abstract::The clinical outcome of advanced-stage Extranodal NK/T cell lymphoma (ENKTL) patients using conventional chemotherapy is extremely poor. The aim of this study was to investigate the outcomes of advanced-stage ENKTL patients treated with non-anthracycline-based chemotherapy followed by upfront autologous stem cell tran...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/s41409-020-01160-2

    authors: Song GY,Yoon DH,Suh C,Moon JH,Baek DW,Kim JS,Lee GW,Yi JH,Park Y,Jung KS,Kim SJ,Yang DH,Kim WS

    更新日期:2020-12-04 00:00:00

  • Lupus inhibitors following bone marrow transplant.

    abstract::Lupus inhibitors have been reported in a number of pathologic states in which there is a disruption of normal immunoregulation. We report here the development of new lupus inhibitors following bone marrow transplantation. Retrospective analysis of 1292 patients undergoing transplantation at the University of Minnesota...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Greeno EW,Haake R,McGlave P,Weisdorf D,Verfaillie C

    更新日期:1995-02-01 00:00:00

  • Correction to: Acute respiratory failure and the kinetics of neutrophil recovery in pediatric hematopoietic cell transplantation: a multicenter study.

    abstract::An amendment to this paper has been published and can be accessed via a link at the top of the paper. ...

    journal_title:Bone marrow transplantation

    pub_type: 已发布勘误

    doi:10.1038/s41409-019-0767-y

    authors: Moffet JR,Mahadeo KM,McArthur J,Hsing DD,Gertz SJ,Smith LS,Loomis A,Fitzgerald JC,Nitu ME,Duncan CN,Hall MW,Pinos EL,Tamburro RF,Simmons RA,Troy J,Cheifetz IM,Rowan CM,Investigators of the Pediatric Acute Lung Injury an

    更新日期:2020-02-01 00:00:00

  • Quality of life and psychological distress of bone marrow transplant recipients: the 'time trajectory' to recovery over the first year.

    abstract::The purpose of this study was to measure the trajectory of psychosocial recovery over the first year after bone marrow transplantation (BMT). BMT patients were assessed at baseline (n = 86), hospital discharge (n = 74), 100 days (n = 64) and at 1 year (n = 45). Participants completed the Functional Assessment of Cance...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:10.1038/sj.bmt.1701115

    authors: McQuellon RP,Russell GB,Rambo TD,Craven BL,Radford J,Perry JJ,Cruz J,Hurd DD

    更新日期:1998-03-01 00:00:00

  • Matched unrelated or matched sibling donors result in comparable outcomes after non-myeloablative HSCT in patients with AML or MDS.

    abstract::The impact of allelic HLA matching in patients with AML and myelodysplastic syndrome (MDS) who receive allogeneic PBSC after a reduced-intensity conditioning (RIC) regimen is unclear. From January 2000 to December 2010, 108 consecutive patients with AML (n=63) and MDS (n=45) received PBSC after RIC in our center, eith...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2013.50

    authors: Robin M,Porcher R,Adès L,Boissel N,Raffoux E,Xhaard A,Larghero J,Gardin C,Himberlin C,Delmer A,Fenaux P,Dombret H,Socié G,Peffault de Latour R

    更新日期:2013-10-01 00:00:00

  • Cytomegalovirus-specific immune recovery following allogeneic HLA-identical sibling transplantation with reduced-intensity preparative regimen.

    abstract::Cytomegalovirus (CMV) represents a major cause of morbidity after allogeneic stem cell transplantation (allo-SCT). Using interferon-gamma-enzyme-linked immunospot (ELISPOT) assay and HLA-peptide tetramers, we analysed 54 patients who received a reduced-intensity conditioning regimen, including fludarabine, busulphan a...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1704442

    authors: Mohty M,Mohty AM,Blaise D,Faucher C,Bilger K,Isnardon D,Sainty D,Gastaut JA,Viens P,Olive D,Gaugler B

    更新日期:2004-04-01 00:00:00

  • Fixed-dose single administration of Pegfilgrastim vs daily Filgrastim in patients with haematological malignancies undergoing autologous peripheral blood stem cell transplantation.

    abstract::Infectious complications are frequent events in patients undergoing high-dose cytotoxic chemotherapy with subsequent autologous peripheral blood stem cell transplantation (PBSCT). To evaluate whether a single subcutaneous injection of pegfilgrastim (6 mg) is as safe and effective as daily filgrastim (5 mug/kg/day), 60...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1704927

    authors: Staber PB,Holub R,Linkesch W,Schmidt H,Neumeister P

    更新日期:2005-05-01 00:00:00

  • Studies of immunologic tolerance to host minor histocompatibility antigens following allogeneic bone marrow transplantation in mice.

    abstract::We showed previously that transplantation of 10(7) unmanipulated C57BL/6 marrow cells to irradiated LP mice yields healthy (B6-LP) chimeras showing no signs of rejection or graft-versus-host disease (GVHD). The aim of this work was to gain more insight into the mechanism(s) responsible for tolerance to host minor hist...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Perreault C,Allard A,Brochu S,Poupart C,Fontaine P,Bélanger R,Gyger M

    更新日期:1990-08-01 00:00:00

  • Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)-an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplant

    abstract::On August 30, 2017, the U.S. Food and Drug Administration (US-FDA) approved tisagenlecleucel (KYMRIAH, Novartis, Basel, Switzerland), a synthetic bioimmune product of anti-CD19 chimeric antigen receptor-T cells (CAR-T), for the treatment of children and young adults with relapsed/refractory B-cell acute lymphoblastic ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/s41409-019-0451-2

    authors: Kansagra AJ,Frey NV,Bar M,Laetsch TW,Carpenter PA,Savani BN,Heslop HE,Bollard CM,Komanduri KV,Gastineau DA,Chabannon C,Perales MA,Hudecek M,Aljurf M,Andritsos L,Barrett JA,Bachanova V,Bonini C,Ghobadi A,Gill SI,Hi

    更新日期:2019-11-01 00:00:00